Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-18 4:59 pm Purchase |
2025-02-10 | 13D | Sionna Therapeutics, Inc. SION |
Atlas Venture Fund XI, L.P. | 2,886,293 6.500% |
2,886,293 (New Position) |
Filing History |
| 2024-11-14 4:32 pm Sale |
2024-09-30 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 5,714,057 5.700% |
-1,628,026 (-22.17%) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Xilio Therapeutics, Inc. XLO |
Atlas Venture Fund XI, L.P. | 0 0.000% |
-2,023,402 (Position Closed) |
Filing History |
| 2024-11-14 4:30 pm Sale |
2024-09-30 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 4,869,681 5.500% |
-1,178,137 (-19.48%) |
Filing History |
| 2024-11-05 6:26 pm Sale |
2024-11-01 | 13D | Third Harmonic Bio, Inc. THRD |
Atlas Venture Fund XI, L.P. | 9,808,190 23.900% |
-505,573 (-4.90%) |
Filing History |
| 2024-02-09 4:09 pm Purchase |
2023-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 7,342,083 9.100% |
15,966 (+0.22%) |
Filing History |
| 2024-02-09 4:08 pm Purchase |
2023-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 6,047,818 6.900% |
39,284 (+0.65%) |
Filing History |
| 2023-11-13 4:15 pm Purchase |
2023-11-03 | 13D | Korro Bio, Inc. KRRO |
Atlas Venture Fund XI, L.P. | 942,075 11.800% |
942,075 (New Position) |
Filing History |
| 2023-02-14 4:31 pm Sale |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Atlas Venture Fund XI, L.P. | 467,529 1.000% |
-1,496,000 (-76.19%) |
Filing History |
| 2023-02-14 4:29 pm Unchanged |
2022-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 7,326,117 14.100% |
0 (Unchanged) |
Filing History |
| 2023-02-14 4:23 pm Sale |
2022-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 6,008,534 8.200% |
-1,201,708 (-16.67%) |
Filing History |
| 2022-09-29 4:30 pm Purchase |
2022-09-19 | 13D | Third Harmonic Bio, Inc. THRD |
Atlas Venture Fund XI, L.P. | 10,313,763 25.600% |
10,313,763 (New Position) |
Filing History |
| 2022-02-11 5:04 pm Sale |
2021-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 7,326,117 14.200% |
-814,013 (-10.00%) |
Filing History |
| 2022-02-11 5:03 pm Sale |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Atlas Venture Fund XI, L.P. | 1,963,529 5.600% |
-242,883 (-11.01%) |
Filing History |
| 2022-02-11 5:03 pm Purchase |
2021-06-01 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
Atlas Venture Fund XI, L.P. | 7,210,242 11.600% |
7,210,242 (New Position) |
Filing History |
| 2021-11-05 4:43 pm Purchase |
2021-10-26 | 13G | Xilio Therapeutics, Inc. XLO |
Atlas Venture Fund XI, L.P. | 2,023,402 7.600% |
2,023,402 (New Position) |
Filing History |
| 2021-02-16 5:28 pm Purchase |
2020-12-31 | 13G | Dyne Therapeutics, Inc. DYN |
Atlas Venture Fund XI, L.P. | 8,140,130 17.900% |
8,140,130 (New Position) |
Filing History |
| 2021-02-16 5:27 pm Sale |
2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Atlas Venture Fund XI, L.P. | 2,206,412 6.400% |
-500,000 (-18.47%) |
Filing History |